Key result
The endothelin-1 receptor antagonist BQ-123 significantly reduced myocardial infarct size by 40% compared to vehicle in a canine model of coronary occlusion and reperfusion.
Why the study?
Does BQ-123 reduce infarct size in a canine model of coronary occlusion and reperfusion?
Does BQ-123 reduce infarct size in a canine model of coronary occlusion and reperfusion?
Effect estimate: 40% reduction
The endothelin-1 receptor antagonist BQ-123 significantly reduces myocardial infarct size in a canine model of ischemia-reperfusion, suggesting endothelin-1 release contributes to infarction pathogenesis.
No takes yet. Share an insight, caveat, or question.
May warrant testing endothelin antagonists in human MI; leaves open translation from canine models.
Grover et al. (1993) studied Myocardial ischaemia and infarction. BQ-123 vs. Vehicle was evaluated on Infarct size (40% reduction). The endothelin-1 receptor antagonist BQ-123 significantly reduced myocardial infarct size by 40% compared to vehicle in a canine model of coronary occlusion and reperfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: